You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國中藥(00570.HK)中期淨利9.3億元 同比增加27.0%
格隆匯 08-20 22:39

格隆匯8月20日丨中國中藥(00570.HK)公吿,截至2021年6月30日止6個月中期業績,營業額合計81.49億元,同比增加22.4%;公司股權持有人應占溢利9.3億元,同比增加27.0%;每股基盈利18.46人民幣分;建議中期每股股息6.66港仙。

近年來,醫藥行業運行態勢整體良好,各項醫改政策及實施細則密集出台,有利於提升行業規範化程度,為醫藥各領域實現轉型和發展提供了良好的宏觀環境。中醫藥行業的競爭格局和未來發展趨勢亦愈發清晰,疊加後疫情時代經濟社會和市場環境的變化,對集團業務發展和戰略規劃產生了重大而深遠的影響。

2021年上半年,集團繼續緊緊圍繞"全面建設可持續、互協同、共發展的中藥大健康全產業鏈,打造行業領先水平的中藥大健康產業集團"的發展目標,穩固工業製造領域優勢,積極調整各項戰略舉措,不斷加大科研投入,持續提升內部治理水平,全力以赴迎接市場新變化,為完成全年目標任務打下堅實基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account